As of 3:27pm ET
| -0.01 / -1.06%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 2.76, with a high estimate of 4.09 and a low estimate of 1.43. The median estimate represents a +196.44% increase from the last price of 0.93.
The current consensus among 2 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.